Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System

被引:27
|
作者
Alva, Shridhara [1 ]
Brazg, Ronald [2 ]
Castorino, Kristin [3 ]
Kipnes, Mark [4 ]
Liljenquist, David R. [5 ]
Liu, Hanqing [1 ]
机构
[1] Abbott Diabet Care, Alameda, CA 94502 USA
[2] Rainier Clin Res Ctr, Renton, WA USA
[3] Sansum Diabet Res Inst, Santa Barbara, CA USA
[4] Diabet & Glandular Dis Clin, San Antonio, TX USA
[5] Rocky Mt Diabet Ctr, Idaho Falls, ID USA
关键词
FSL3 CGM system; FSL2 CGM system; Continuous glucose monitoring; Self-monitoring blood glucose; YSI reference;
D O I
10.1007/s13300-023-01385-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionWe have evaluated the performance of the FreeStyle Libre (R) 3 continuous glucose monitoring system (FSL3) compared to (1) the venous plasma reference for participants aged >= 6 years and (2) the fingerstick capillary blood glucose (BG) reference for pediatric participants aged 4 and 5 years. The analytical performance of the third-generation factory-calibrated FSL3 CGM system was compared to the plasma venous blood glucose reference using the YSI 2300 STAT PLUS Glucose and Lactate Analyzer (the YSI reference) and the self-monitoring blood glucose (SMBG) reference for participants aged >= 6 years and participants aged 4 and 5 years, respectively.MethodsA total of 108 participants aged >= 4 years with type 1 or type 2 diabetes from four sites in the USA were enrolled in the study. The data of 100 participants were ultimately evaluated. Adult participants (aged >= 18 years) participated in three in-clinic sessions, and pediatric participants (aged 4-17 years) participated in up to two in-clinic sessions, all stratified to provide data for days 1, 2, 3, 7, 8, 9, 12, 13 or 14 of sensor wear. Performance evaluation included accuracy measures, such as proportion of CGM values that fell within +/- 20% or +/- 20 mg/dL (1.1 mmol/L) of the reference glucose values, and difference measures, such as the mean absolute relative difference (MARD) between the CGM and reference values.ResultsData from the 100 study participants were analyzed. The overall MARD was 7.8%, and 93.4% of the CGM values were within +/- 20% or +/- 20 mg/dL of the YSI reference for participants aged >= 6 years, with 6845 CGM-YSI matched pairs. The performance was stable over the 14-day wear period. For participants aged 4-5 years, MARD was 10.0%, and 88.9% of the CGM values were within 20%/20 mg/dL compared to a SMBG reference. No serious adverse events were reported.ConclusionsThe FSL3 CGM system demonstrated accurate performance across the dynamic glycemic range during the 14-day sensor wear period.
引用
收藏
页码:767 / 776
页数:10
相关论文
共 50 条
  • [21] Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes
    Slover, Robert H.
    Tryggestad, Jeanie B.
    DiMeglio, Linda A.
    Fox, Larry A.
    Bode, Bruce W.
    Bailey, Timothy S.
    Brazg, Ronald
    Christiansen, Mark P.
    Sherr, Jennifer L.
    Tsalikian, Eva
    Kaiserman, Kevin B.
    Sullivan, Ashley
    Huang, Suiying
    Shin, John
    Lee, Scott W.
    Kaufman, Francine R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (09) : 576 - 584
  • [22] Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes
    Laffel, Lori M.
    Bailey, Timothy S.
    Christiansen, Mark P.
    Reid, Jennifer L.
    Beck, Stayce E.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2023, 17 (04): : 962 - 967
  • [23] Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study
    Bailey, Timothy S.
    Liljenquist, David R.
    Denham, Douglas S.
    Brazg, Ronald L.
    Ioacara, Sorin
    Masciotti, James
    Ghosh-Dastidar, Samanwoy
    Tweden, Katherine S.
    Kaufman, Francine R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2025,
  • [24] 14-day continuous infusion ifosfamide in advanced refractory sarcomas.
    Singh, Arun S.
    Sankhala, Kamalesh Kumar
    Mukherjee, Arnob
    Narasimha, Vivek
    Chmielowski, Bartosz
    Quon, Doris V.
    Chua, Vicky
    Chawla, Sant P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] SUITABILITY OF CISPLATIN SOLUTIONS FOR 14-DAY CONTINUOUS INFUSION BY AMBULATORY PUMP
    HRUBISKO, M
    MCGOWN, AT
    PRENDIVILLE, JA
    RADFORD, JA
    THATCHER, N
    FOX, BW
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 29 (03) : 252 - 255
  • [26] Accuracy of a continuous glucose monitoring system in dogs and cats with diabetic ketoacidosis
    Reineke, Erica L.
    Fletcher, Daniel J.
    King, Lesley G.
    Drobatz, Kenneth J.
    JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE, 2010, 20 (03) : 303 - 312
  • [27] Accuracy of a subcutaneous continuous glucose monitoring system in critically ill patients
    Rijkenberg, S.
    van Steen, S. C. J.
    DeVries, J. H.
    van der Voort, P. H. J.
    DIABETOLOGIA, 2016, 59 : S412 - S413
  • [28] Accuracy of a continuous glucose monitoring system (CGMS): still room for improvement
    Heckermann, S.
    Nosek, L.
    Zijlstra, E.
    Heise, T.
    DIABETOLOGIA, 2010, 53 : S26 - S27
  • [29] Accuracy of a Continuous Glucose Monitoring System (CGMS): Still Room for Improvement
    Heckermann, Sascha
    Nosek, Leszek
    Zijlstra, Eric
    Heise, Tim
    DIABETES, 2010, 59 : A131 - A132
  • [30] Accuracy of the 5-day freestyle navigator continuous glucose monitoring system - Comparison with frequent laboratory reference measurements
    Weinstein, Richard L.
    Bugler, Jolyon R.
    Schwartz, Sherwyn L.
    Peyser, Thomas A.
    Brazg, Ronald L.
    McGarraugh, Geoffrey V.
    DIABETES CARE, 2007, 30 (05) : 1125 - 1130